Literature DB >> 1103749

Enteropathogenic Esch. coli gastroenteritis in premature infants and children treated with fosfomycin.

F Baquero, E Canedo, A RODRIGUEZ, E Jaso.   

Abstract

Forty-two infants, some premature, with enteropathogenic Esch. coli (EPEC) gastroenteritis were treated with an oral suspension of fosfomycin in a dose of 100 and 200 mg/kg per day. After the treatment there were 11 secondary clinical infections (6 reinfections and 5 relapses) which received a second treatment with fosfomycin. In total, 53 treatments were made with fosfomycin and in 92% of the cases there was both clinical and bacteriological cure. 93% of the EPEC strains were sensitive to fosfomycin in vitro, their minimum inhibitory concentrations being less than 64 mug/ml. The concentration of fosfomycin in blood and faeces was assayed by a diffusion plate microbiological method in a group of these children, showing that this antibiotic is partly absorbed and the rest eliminated in the faeces, where its concentration was found to be very high. Tolerance of the product was good, and there were neither toxic nor side effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1103749      PMCID: PMC1544428          DOI: 10.1136/adc.50.5.367

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

1.  Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis.

Authors:  K C Haltalin; J D Nelson; H T Kusmiesz
Journal:  Arch Dis Child       Date:  1973-04       Impact factor: 3.791

2.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

3.  Phosphonomycin. 3. Evaluation in vitro.

Authors:  D Hendlin; B M Frost; E Thiele; H Kropp; M E Valiant; B Pelak; B Weissberger; C Cornin; A K Miller
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

4.  Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae.

Authors:  B Aserkoff; J V Bennett
Journal:  N Engl J Med       Date:  1969-09-18       Impact factor: 91.245

5.  Clinical pharmacology and in vitro activity of phosphonomycin.

Authors:  D G Kestle; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

6.  Phosphonomycin. I. Discovery and in vitro biological characterization.

Authors:  E O Stapley; D Hendlin; J M Mata; M Jackson; H Wallick; S Hernandez; S Mochales; S A Currie; R M Miller
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

7.  Pharmacodynamics of phosphonomycin after oral administration in man.

Authors:  E L Foltz; H Wallick; C Rosenblum
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

8.  Phosphonomycin. V. Evaluation in mice.

Authors:  A K Miller; B M Frost; M E Valiant; H Kropp; D Hendlin
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

9.  Effect of antibiotic treatment on duration of excretion of Salmonella typhimurium by children.

Authors:  J M Dixon
Journal:  Br Med J       Date:  1965-12-04

10.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

  10 in total
  1 in total

1.  Genetic analysis of Escherichia coli O111:B4, a strain of medical and biochemical interest.

Authors:  W G Coleman; P J Goebel; L Leive
Journal:  J Bacteriol       Date:  1977-05       Impact factor: 3.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.